You are here: Industry Insights > ILUMYA

News List

Sun Pharma declares five-year positive results for ILUMYA (tildrakizumab-asmn) expresspharma
November 02, 2020
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses.
Sun Pharma launches ILUMYA (tildrakizumab) in Japan expresspharma
September 23, 2020
It is indicated for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies.
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA for Middle East & North Africa regions expresspharma
June 16, 2020
ILUMYA (tildrakizumab) is an US FDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sun Pharma’s ILUMYA improves joint and skin symptoms of Psoriatic Arthritis biospectrumasia
June 16, 2019
Over 71% of Patients Treated with ILUMYA™ Achieved ACR20 Response After 24 Weeks, with Significant Improvement as Early as 8 Weeks
Sun Pharma announces Australian TGA approval of ILUMYA biospectrumasia
September 29, 2018
ILUMYA is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European Commission approved it in September 2018
FDA approves Sun Pharma’s ILUMYA for treating plaque psoriasis biospectrumasia
March 23, 2018
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.